Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • Markets
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Price Target
  • Small Cap

Dow To $45? Here Are 5 Other Price Target Changes For Tuesday

By Lisa Levin
Today, 6:46 PM
Jefferies cut the price target on Dow Inc. (NYSE: DOW) from $71 to $45. Jefferies analyst Laurence Alexander also downgraded the stock from Buy to Hold. Dow shares fell 0.8% to $50.55 in pre-market trading.

BRZE

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

HC Wainwright & Co. Maintains Buy on Ventyx Biosciences, Raises Price Target to $50

By Benzinga Newsdesk
Today, 6:46 PM
HC Wainwright & Co. analyst Emily Bodnar maintains Ventyx Biosciences (NASDAQ:VTYX) with a Buy and raises the price target from $36 to $50.

VTYX

Read More
5 minute read
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday

By Lisa Levin
Today, 6:46 PM
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

AKTX

Read More
2 minute read
  • Markets
  • Movers
  • News
  • Pre-Market Outlook
  • Small Cap
  • Trading Ideas

NIO, Lucid Group And Other Big Gainers From Monday

By Lisa Levin
Today, 6:46 PM
U.S. stocks closed higher with the Dow Jones surging more than 200 points on Monday. Here is the list of some big stocks moving higher in the previous session.

ASAN

Read More
2 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Small Cap

S&P 500 Rises 1%, InMed Pharmaceuticals Shares Spike Higher

By Lisa Levin
Today, 6:46 PM
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Monday.

AKTX

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights
Today, 6:46 PM
 

AKTX

Read More
4 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin
Today, 6:46 PM
Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.

AKTX

Read More
3 minute read
  • Commodities
  • Earnings
  • Eurozone
  • Global
  • Intraday Update
  • Markets
  • News
  • Penny Stocks
  • Small Cap

Dow Jumps 250 Points; Crude Oil Rises Over 1%

By Lisa Levin
Today, 6:46 PM
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 250 points on Monday.

AKTX

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Oppenheimer Maintains Outperform on Ventyx Biosciences, Raises Price Target to $65

By Benzinga Newsdesk
Today, 6:46 PM
Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and raises the price target from $40 to $65.

VTYX

Read More
13 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For September 7, 2022

By Benzinga Insights
Today, 6:46 PM
Upgrades

ACCD

Posts navigation

Previous 1 2 3 … 5 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service